TORONTO, February 05, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI ® (maralixibat) for the treatment of ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する